Docetaxel-induced Scleroderma in A Breast Cancer Patient: A Case Report

Murat Özgür Kılıç, Metin Yalaza, Celal İsmail Bilgiç, Cenap Dener

Department of General Surgery, Turgut Ozal University Faculty of Medicine, Ankara, Turkey

ABSTRACT

Paclitaxel and docetaxel are antineoplastic drugs derived from the yew tree, *Taxus brevifolia*. They are the members of the taxane family and act by inhibiting mitotic activity due to the suppression of microtubule depolymerization. They are used in the treatment of ovarian cancer, breast cancer, gastric cancer, small cell lung cancer, and head and neck cancer. In addition to side effects such as cardiotoxicity, neutropenia, arthralgia, and myalgia, they may also cause alopecia, urticaria, mucositis, acral erythema, pustular dermatitis, erythema multiforme, and scleroderma-like mucocutaneous lesions. Scleroderma is among the uncommon side effects of taxane antineoplastic agents. As was the case in few cases in literature, it usually begins with edematous changes in the proximal aspect of the extremities, and subsequently, sclerosis is developed in the skin. Scleroderma, which usually regresses with the discontinuation of the drug and with steroid therapy, may lead to severe contractions that require physical therapy and rehabilitation in some patients. In this paper, we presented a 60-year-old female patient in whom scleroderma developed because docetaxel chemotherapy for breast cancer because it is encountered rarely.

Keywords: Taxoids, scleroderma, breast cancer

Introduction

Paclitaxel and docetaxel are antineoplastic agents of the taxane family and act by inhibiting mitosis. They are used in the treatment of solid tumors in ovarian cancer, breast cancer, small cell lung cancer, and head and neck cancers. In many recent studies on adjuvant therapy of breast cancer, it has been demonstrated that chemotherapy regimens including taxane improve survival and decrease recurrence compared with standard FAC (5-fluorouracil, doxorubicin, and cyclophosphamide) chemotherapy (1, 2). Nevertheless, in addition to side effects such as neutropenia, arthralgia, and cardiotoxicity, they may cause acral erythema, pustular dermatitis, erythema multiforme, and scleroderma-like mucocutaneous lesions (3). Scleroderma is an autoimmune disease of connective tissue with an unknown etiology and courses with increase in connective tissue and fibrosis. Scleroderma-like mucocutaneous lesions are rare adverse events encountered because of docetaxel, and we think that this should be kept in mind during the follow-up of breast cancer patients.

Case Presentation

A 59-year-old female patient underwent modified right radical mastectomy and axillary dissection due to multicentric invasive ductal carcinoma of the right breast. The pathology report revealed that the tumor consisted of numerous millimetric multiple foci, the largest being 3.5 cm in diameter. In addition to extensive lymphovascular tumor emboli and millimetric satellite foci in all quadrants, there were tumor emboli in the lymphatics of the areola and breast skin. Furthermore, the tumor showed extensive perineural invasion. The immunohistochemical examination demonstrated that estrogen and progesterone receptors were diffuse nuclear (-) and CerbB-2 was (-). Invasive ductal carcinoma metastasis and extracapsular adipose tissue invasion were detected in 6 of 14 lymph nodes obtained from the axillary specimen. Chemotherapy, radiotherapy, and hormonal therapy were decided to be initiated for the patient. A chemotherapy regimen consisting of docetaxel, doxorubicin, and cyclophosphamide (TAC) was started. After the second cure of docetaxel, the patient developed redness and edema followed by induration on the skin of the left lower extremity first, and after a while, the same lesion appeared on the right arm, and the photos of the lesions were taken after the patient provided informed consent (Figure 1-3). Dermatology and rheumatology consultations performed for this reason suggested that these lesions were due to a connective tissue disease. Drug eruptions, urticaria, eczema, local dystrophy, and other diseases with Raynaud's phenomenon were also observed in the differential diagnosis, and then various diagnostic tests were performed. On blood analysis, ANA (antinuclear antibody-centromere antibody) was positive (1/320). Anticardiolipin, antiphospholipid, ANCA, ENA, CCP antibodies, and other rheumatological parameters were found to be negative. Based on all clinical and laboratory findings and the 2013 ACR/EULAR Classification Criteria for Scleroderma, the patient was diagnosed with

Address for Correspondence:

Murat Özgür Kılıç, Department of General Surgery, Turgut Ozal University Faculty of Medicine, Ankara, Turkey
Phone: +90 505 357 31 22 e-mail: murat05ozgur@hotmail.com

Received: 28.07.2014
Accepted: 14.08.2014

Figure 1. Cutaneous fibrosis in the dorsum of the right hand and arm

Figure 2. Cutaneous fibrosis in the palms of the right hand and arm

scleroderma. Skin biopsy was not performed because the patient was receiving chemotherapy and because of the probability of poor wound healing. Cyclophosphamide and prednisolone were commenced. Five thousand centigray radiotherapy was delivered in 25 fractions to the right chest wall and axillary fossa at the radiation oncology unit. However, femara was commenced at a single dose daily. Approximately a year later, the lesion on her left leg completely disappeared, but the one on her right arm partially regressed.

Discussion and Conclusions

Taxanes are antineoplastic agents derived from the yew tree, *Taxus brevifolia*, and they act by inhibiting mitosis. They are used in the treatment of ovarian cancer, breast cancer, small cell lung cancer, and head and neck cancers. Recently, numerous studies were performed on taxane-based chemotherapies. Multicenter studies such as BCIRG 001 and GEICAM/2003-02 demonstrated that chemotherapy regimens including taxane improve survival and reduce recurrence rates compared with the standard FAC chemotherapy (1, 2). Taxanes, as well as other antineoplastic agents, have many toxic effects. In addition to side effects such as cardiotoxicity, mucositis, neutropenia, arthralgia, and myalgia, they may also lead to some mucocutaneous lesions. Although hypersensitivity lesions such as urticaria are more common, there are patients in literature who developed erythematous and edematous skin reactions, erythema multiforme, and systemic lupus erythematosus after taxoid administration (3-6). Scleroderma-like skin lesions following docetaxel have rarely been reported in literature (7-10). There is no case reported from Turkey. Battafarano et al. (7) presented three

Figure 3. Scleroderma affecting the right hand and arm. Improvement in erythema, dyspigmentation, and skin thickness demonstrated over a 3-month period

patients who developed sclerotic skin lesions in the lower extremities following docetaxel administration. Cleveland (8) reported extensive edema followed by fibrosis after docetaxel in a metastatic breast cancer patient in whom the signs were rapidly improved when the drug was discontinued. Likewise, Hassett (9) also identified scleroderma-like skin lesions due to docetaxel in a breast cancer patient. In their study that included 5 patients with metastatic breast cancer who developed scleroderma following taxane administration, Itoh et al. (11) reported edema in the distal aspect of the extremities followed by sclerosis in the skin. While all these patients received steroid therapy, three required rehabilitation. It is known that similar skin lesions also develop with paclitaxel, another taxane agent (12-15). Tanaka et al. (16) also presented a patient with metastatic breast cancer who developed cystoid macular edema due to paclitaxel and emphasized the importance of mucocutaneous lesions as a rarely seen side effect that could substantially affect the quality of life. Sclerotic skin lesions may either be limited to a certain region of the body or be extensive (8, 9). In the present case, extensive sclerotic skin lesions appeared in the lower left and upper right extremities after docetaxel administration. Restriction occurred in the hand, arm, and foot movements of the patient. This condition quite unfavorably influenced the patient's quality of life. The lesions began to regress after the chemotherapy was ended and steroid therapy was commenced.

Taxoid antineoplastic agents, which are being increasingly used in the adjuvant therapy of breast cancer, have mucocutaneous adverse events in addition to their many toxic effects. Although scleroderma is rarely encountered, it should always be kept in mind that it may develop after docetaxel administration. Moreover, a systemic approach is needed in the diagnosis and treatment of these cutaneous lesions.

Informed Consent: Written informed consent was obtained from the patient who participated in this study.

Peer-review: Externally peer-reviewed.

Author contributions: Concept - M.Ö.K., C.D.; Design- M.Ö.K., C.İ.B.; Supervision - C.İ.B., C.D.; Funding - M.Ö.K, M.Y.; Materials - M.Ö.K., M.Y.; Data Collection &/or Processing - M.Ö.K., M.Y.; Analysis &/or Interpretation - M.Ö.K., C.İ.B.; Literature Review - M.Ö.K, C.İ.B.; Writer - M.Ö.K.; Critical Review - M.Ö.K. , C.D.

Conflict of Interest: No conflict of interest was declared by the authors.

Financial Disclosure: The authors declared that this study has received no financial support.

References

- Mackey JR, Martin M, Pienkowski T, Rolski J, Guastalla JP, Sami A, Glaspy J, Juhos E, Wardley A, Fornander T, Hainsworth J, Coleman R, Modiano MR, Vinholes J, Pinter T, Rodríguez-Lescure A, Colwell B, Whitlock P, Provencher L, Laing K, Walde D, Price C, Hugh JC, Childs BH, Bassi K, Lindsay MA, Wilson V, Rupin M, Houé V, Vogel C; TRIO/BCIRG 001 investigators. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial. *Lancet Oncol* 2013; 14:72-80. (PMID: 23246022) [\[CrossRef\]](#)
- Martín M, Ruiz A, Ruiz Borrego M, Barnadas A, González S, Calvo L, Margelí Vila M, Antón A, Rodríguez-Lescure A, Seguí-Palmer MA, Muñoz-Mateu M, Dorca Ribugent J, López-Vega JM, Jara C, Espinosa E, Mendiola Fernández C, Andrés R, Ribelles N, Plazaola A, Sánchez-Rovira P, Salvador Bofill J, Crespo C, Carabantes FJ, Servitja S, Chacón JJ, Rodríguez CA, Hernando B, Álvarez I, Carrasco E, Lluch A. Fluorouracil, Doxorubicin, and Cyclophosphamide (FAC) Versus FAC Followed by Weekly Paclitaxel As Adjuvant Therapy for High-Risk, Node-Negative Breast Cancer: Results From the GEICAM/2003-02 Study. *Clin Oncol* 2013; 31:2593-2599. (PMID: 23733779) [\[CrossRef\]](#)
- Cohen PR. Photodistributed erythema multiforme: paclitaxel-related, photosensitive conditions in patients with cancer. *J Drugs Dermatol* 2009; 8:61-64. (PMID: 19180897)
- Dasanu CA, Alexandrescu DT. Systemic lupus erythematosus associated with paclitaxel use in the treatment of ovarian cancer. *South Med J*. 2008; 101:1161-1162. (PMID: 19088531) [\[CrossRef\]](#)
- Moisisdis C, Möbus V. Erythema multiforme major following docetaxel. *Arch Gynecol Obstet* 2005; 271:267-269. (PMID: 15243755) [\[CrossRef\]](#)
- Chew L, Chuen VS. Cutaneous reaction associated with weekly docetaxel administration. *J Oncol Pharm Pract* 2009; 15:29-34. (PMID: 18753180) [\[CrossRef\]](#)
- Battafarano DF, Zimmerman GC, Older SA, Keeling JH, Burris HA. Docetaxel (Taxotere) associated scleroderma-like changes of the lower extremities. A report of three cases. *Cancer* 1995; 76:110-115. (PMID: 8630861)
- Cleveland MG, Ajaikumar BS, Reganti R. Cutaneous fibrosis induced by docetaxel: a case report. *Cancer*. 2000; 88:1078-1081. (PMID: 10699898)
- Hassett G, Harnett P, Manolios N. Scleroderma in association with the use of docetaxel (taxotere) for breast cancer. *Clin Exp Rheumatol*. 2001; 19:197-200. (PMID: 11326485)
- Gotaskie GE, Andreassi BF. Paclitaxel: a new antimitotic chemotherapeutic agent. *Cancer Pract*. 1994; 2:27-33. (PMID: 7914453)
- Itoh M, Yanama K, Kobayashi T, Nakagawa H. Taxane-induced scleroderma. *Br J Dermatol* 2007; 156:363-367. (PMID: 17223879) [\[CrossRef\]](#)
- Pedersen JV, Jensen S, Krarup-Hansen A, Riis L. Scleroderma induced by paclitaxel. *Acta Oncol*. 2010; 49:866-868. (PMID: 20446892) [\[CrossRef\]](#)
- Läuchli S, Trüeb RM, Fehr M, Hafner J. Scleroderma-like drug reaction to paclitaxel (Taxol). *Br J Dermatol* 2002; 147:619-621. (PMID: 12207621) [\[CrossRef\]](#)
- Kawakami T, Tsutsumi Y, Soma Y. Limited cutaneous systemic sclerosis induced by paclitaxel in a patient with breast cancer. *Arch Dermatol* 2009; 145:97-98. (PMID: 19153362) [\[CrossRef\]](#)
- De Angelis R, Bugatti L, Cerioni A, Del Medico P, Filosa G. Diffuse scleroderma occurring after the use of paclitaxel for ovarian cancer. *Clin Rheumatol* 2003; 22:49-52. (PMID: 12605319) [\[CrossRef\]](#)
- Tanaka Y, Bando H, Hara H, Ito Y, Okamoto Y. Cystoid macular edema induced by nab-paclitaxel. *Breast Cancer* 2012 May 17. [Epub ahead of print] (PMID: 22592399)